Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review.
| Autor: | Kengne AP; Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa., Brière JB; Global Value Access & Pricing, Servier International, Suresnes, France., Zhu L; Health Economics and Market Access, Amaris Consulting, Barcelona, Spain., Li J; Health Economics and Market Access, Amaris Consulting, Shanghai, China., Bhatia MK; Health Economics and Market Access, Amaris Consulting, Toronto, Canada., Atanasov P; Health Economics and Market Access, Amaris Consulting, Barcelona, Spain., Khan ZM; Zebgene LLC, Malvern, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Jan; Vol. 24 (1), pp. 143-154. Date of Electronic Publication: 2024 Jan 18. |
| DOI: | 10.1080/14737167.2023.2266135 |
| Abstrakt: | Introduction: We aimed to summarize evidence on the effect of poor medication adherence on clinical outcomes and health resource utilization (HRU) among patients with hypertension and/or dyslipidemia. Areas Covered: A systematic review of studies reporting clinical outcomes and HRU for patients by status of adherence to antihypertensives and/or lipid-lowering medications was searched using Embase, MEDLINE, and MEDLINE In-Process and supplemented by manual searches of conference abstracts. In total, 45 studies were included, with most being retrospective observational studies ( n = 36). Patients with poor adherence to antihypertensives and lipid-lowering medications compared with those with good adherence showed less reduction of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-c) after 6-12 months follow-up (∆ systolic BP: 1.2 vs. -4.5 mmHg; ∆LDL-c: -14.0 to -18.9 vs. -34.1 to -42.0 mg/dL). Poor adherence was also significantly associated with a higher risk of cardiovascular events (HR: 1.1-1.9) and mortality (HR: 1.4-1.8) in patients with hypertension and dyslipidemia and increased HRU (i.e. outpatient visits, risk of cardiovascular-related and all-cause hospitalization, annual inpatient days, total health-care costs). Expert Opinion: Poor adherence is associated with poor clinical outcomes and increased HRU, highlighting the need to enhance medication adherence in patients with hypertension and/or dyslipidemia. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|